semaglutide news oct 26 2025 The FDA has approved the first GLP-1 pill for weight loss, a milestone in the growth of the revolutionary drugs. The drug, a once-a-day Wegovy tablet, is also approved for reducing cardiovascular GLP-1 trends 2025: real-world data,

A lack of protein in the diet can lead to weak, brittle hair or even hair loss

It's important to note that whilst Ozempic is licensed specifically for type 2 diabetes, a higher-dose formulation of semaglutide (Wegovy) has been approved by the MHRA for weight management in adults with obesity or overweight with weight-related comorbidities

Clinical studies have explored the therapeutic effectiveness of the exenatide GLP-1 drug in Parkinson's disease, with inconsistent findings

April 2025: Novo Nordisk committed USD 1.09 billion to expand Montes Claros fill-finish capacity, with operations slated for late 2026

The COA potency shows the verified active amount of GLP confirmed through lab testing, which may vary slightly from the labeled amount

Semaglutide begins its biological action almost immediately after injection, as it circulates through your bloodstream and binds to GLP-1 receptors throughout your digestive tract and brain